POU4F3
Basic information
Region (hg38): 5:146338839-146341728
Previous symbols: [ "DFNA15", "DFNA52", "DFNA42" ]
Links
Phenotypes
GenCC
Source:
- autosomal dominant nonsyndromic hearing loss 15 (Strong), mode of inheritance: AD
- autosomal dominant nonsyndromic hearing loss 15 (Strong), mode of inheritance: AD
- autosomal dominant nonsyndromic hearing loss (Supportive), mode of inheritance: AD
- nonsyndromic genetic hearing loss (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Deafness, autosomal dominant 15 | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Audiologic/Otolaryngologic | 9506947; 18228599; 18347256; 19372648; 19462854; 20434433; 22938506 |
ClinVar
This is a list of variants' phenotypes submitted to
- Autosomal dominant nonsyndromic hearing loss 15 (7 variants)
- not provided (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the POU4F3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 27 | 34 | ||||
missense | 84 | 93 | ||||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 11 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 5 | |||||
Total | 9 | 14 | 88 | 30 | 6 |
Variants in POU4F3
This is a list of pathogenic ClinVar variants found in the POU4F3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-146338855-G-A | Likely benign (Dec 23, 2018) | |||
5-146339034-C-A | Autosomal dominant nonsyndromic hearing loss 15 | Uncertain significance (Jan 13, 2018) | ||
5-146339069-C-A | Autosomal dominant nonsyndromic hearing loss 15 | Uncertain significance (Jan 13, 2018) | ||
5-146339136-G-A | Autosomal dominant nonsyndromic hearing loss 15 | Conflicting classifications of pathogenicity (Apr 03, 2023) | ||
5-146339138-C-T | Inborn genetic diseases | Uncertain significance (Feb 07, 2023) | ||
5-146339143-G-A | Uncertain significance (Dec 12, 2023) | |||
5-146339147-T-C | Uncertain significance (Mar 02, 2022) | |||
5-146339148-GC-AA | Uncertain significance (Jan 22, 2024) | |||
5-146339148-GC-G | Autosomal dominant nonsyndromic hearing loss 15 | Pathogenic (Jul 28, 2022) | ||
5-146339151-C-G | Uncertain significance (Apr 04, 2023) | |||
5-146339164-GA-G | Autosomal dominant nonsyndromic hearing loss 15 | Pathogenic (Aug 01, 2020) | ||
5-146339166-A-C | Inborn genetic diseases • POU4F3-related disorder | Uncertain significance (Nov 02, 2022) | ||
5-146339176-TC-T | Autosomal dominant nonsyndromic hearing loss 15 | Pathogenic (May 22, 2022) | ||
5-146339178-C-T | POU4F3-related disorder | Likely benign (Sep 11, 2024) | ||
5-146339182-C-T | Likely benign (May 23, 2023) | |||
5-146339183-T-G | Uncertain significance (Dec 23, 2021) | |||
5-146339190-T-A | Likely benign (Mar 01, 2023) | |||
5-146339197-G-A | Uncertain significance (May 02, 2023) | |||
5-146339202-C-T | not specified • Autosomal dominant nonsyndromic hearing loss 15 | Benign (Jan 26, 2024) | ||
5-146339208-C-A | not specified | Likely benign (Feb 14, 2019) | ||
5-146339210-G-A | Uncertain significance (Nov 04, 2022) | |||
5-146339212-G-C | Inborn genetic diseases | Uncertain significance (Jan 02, 2024) | ||
5-146339215-T-C | not specified | Uncertain significance (May 23, 2023) | ||
5-146339225-C-A | Autosomal dominant nonsyndromic hearing loss 15 | Uncertain significance (Jan 13, 2018) | ||
5-146339230-C-T | Likely pathogenic (Apr 01, 2017) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
POU4F3 | protein_coding | protein_coding | ENST00000230732 | 2 | 1497 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.920 | 0.0799 | 125730 | 0 | 2 | 125732 | 0.00000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.661 | 208 | 183 | 1.14 | 0.00000939 | 2210 |
Missense in Polyphen | 40 | 54.595 | 0.73266 | 688 | ||
Synonymous | -2.74 | 105 | 74.8 | 1.40 | 0.00000438 | 698 |
Loss of Function | 2.63 | 0 | 8.08 | 0.00 | 3.79e-7 | 93 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000176 | 0.0000176 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as a transcriptional activator (PubMed:18228599). Acts by binding to sequences related to the consensus octamer motif 5'-ATGCAAAT-3' in the regulatory regions of its target genes (PubMed:18228599). Involved in the auditory system development, required for terminal differentiation of hair cells in the inner ear (By similarity). {ECO:0000250|UniProtKB:Q63955, ECO:0000269|PubMed:18228599}.;
Recessive Scores
- pRec
- 0.156
Intolerance Scores
- loftool
- 0.111
- rvis_EVS
- -0.54
- rvis_percentile_EVS
- 20.54
Haploinsufficiency Scores
- pHI
- 0.895
- hipred
- Y
- hipred_score
- 0.755
- ghis
- 0.502
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.431
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pou4f3
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; vision/eye phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- visual perception;sensory perception of sound;vestibulocochlear nerve development;retinal ganglion cell axon guidance;inner ear morphogenesis;inner ear auditory receptor cell differentiation;positive regulation of transcription by RNA polymerase II;axon extension;neuromuscular process controlling balance;neuron apoptotic process
- Cellular component
- nucleus;nucleoplasm;cytoplasm
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA-binding transcription factor activity